Ensera announces partnership with Stevanato Group for commercialization services for Alina® and Aidaptus® platforms
Ensera and Stevanato Group alliance
Through the partnership, pharmaceutical companies using Alina®, Stevanato Group's pen injector platform, and Aidaptus®, an autoinjector platform designed by Owen Mumford with engineering and manufacturing support provided by Stevanato Group, can access flexible final assembly, labeling, and secondary packaging services at Ensera's GMP facilities in Europe, the United States, and Asia.
The alliance reflects both companies’ commitment in supporting pharmaceutical companies navigating the complex commercialization, localization, supply chain and regulatory requirements associated with launching combination products across global markets.
This latest alliance adds to Ensera's growing network of global device platform partners. These collaborations are particularly valuable for pharmaceutical companies launching specialized therapies that require flexible manufacturing models, regional customization, or low to mid-volume commercial supply.
Bobby O'Connor, Ensera's Chief Commercial Officer said: "We're delighted to partner with Stevanato Group to support pharmaceutical companies bringing combination products to market. By combining proven delivery platforms with flexible final assembly and packaging services, we can help customers simplify commercialization and adapt supply strategies to regional market needs."
Darren Hieber, Sales Lead USA & Alliances added "We're proud that an increasing number of leading drug delivery providers are choosing to work with Ensera. These partnerships are helping create more flexible pathways to commercialization for pharmaceutical companies and expanding the support available throughout the product lifecycle."
Michele Monico, President, Drug Delivery Systems & In Vitro Diagnostics at Stevanato Group, commented: "We are pleased to collaborate with Ensera to further support pharmaceutical companies adopting our proprietary drug delivery platforms. As the industry increasingly looks for more integrated pathways to commercialization, this alliance extends our offering downstream through assembly, labeling, and packaging services, broadening the ecosystem around our devices and providing customers with an additional pathway to simplify product launch and supply chain execution."
About Ensera
Ensera is a global CDMO supporting pharmaceutical and medical device companies with device design, final assembly, labeling, and secondary packaging of injectable formats, including autoinjectors and pre-filled syringes.
Its flexible GMP cleanroom operations across Europe, the US and Asia are optimized for low-to-medium batch volumes, supported by integrated quality systems and cold chain infrastructure. An approved assembly partner for market leading autoinjector platforms, Ensera combines device and pharmaceutical expertise to deliver efficient, compliant supply for combination products.
For additional information, visit www.ensera.com.
About Stevanato Group
Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages.
Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation and its engineering excellence are central to its ability to offer value added solutions to clients.
To learn more, visit: www.stevanatogroup.com.
Alliance notice
This alliance is non-exclusive. Both Stevanato Group and Ensera are part of multi-member alliance groups and remain free to enter into other commercial collaborations and partnerships.
Media Contacts
Ensera – Josh Lowth, j.lowth@ensera.com
Stevanato Group – Caterina Tripepi, caterina.tripepi@stevanatogroup.com
Josh Lowth
Ensera
email us here
Visit us on social media:
LinkedIn
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
